By Michelle Gerlovin, PharmD.
Eisai Inc. announced that under the recommendation of the FDA, it will voluntarily withdraw Belviq and Belviq XR from the market due to concerns about a possible increased risk of cancer. The FDA has said they are taking this action because they believe that the risks of Belviq (lorcaserin) outweigh its benefits based on the final review of results from a randomized clinical trial assessing safety. The FDA advised patients taking Belviq should discontinue treatment and talk to a health care professional about alternative weight-loss medicines and weight management programs.
Currently, some PBMs may prefer Belviq on their formularies over other weight loss drugs, so it is possible to see some formulary changes occur in this drug class due to this recall. Truveris can help you assess the impact of this recall and review any formulary changes that are a result of this FDA action.